Claims
- 1. A compound of formula (I): ##STR9## or a pharmaceutically, veterinarily or agriculturally acceptable salt thereof, or a pharmaceutically, veterinarily or agriculturally acceptable solvate of either entity,
- wherein
- R.sup.1 is 2,4,6-trisubstituted phenyl wherein the 2- and 6-substituents are each independently selected from halo and the 4-substituent is selected from C.sub.1 to C.sub.4 alkyl optionally substituted with one or more halo, C.sub.1 to C.sub.4 alkoxy optionally substituted with one or more halo, S(O).sub.n C.sub.1 to C.sub.4 alkyl optionally substituted with one or more halo, halo and pentafluorothio; or 3,5-disubstituted pyridin-2-yl wherein the 3-substituent is halo and the 5-substituent is selected from C.sub.1 to C.sub.4 alkyl optionally substituted with one or more halo, C.sub.1 to C.sub.4 alkoxy optionally substituted with one or more halo, S(O).sub.n C.sub.1 to C.sub.4 alkyl optionally substituted with one or more halo, halo and pentafluorothio;
- R.sup.3 is C.sub.1 to C.sub.4 alkyl optionally substituted with hydroxy or with one or more halo; cyano, C.sub.1 to C.sub.5 alkanoyl or phenyl;
- R.sup.5 is hydrogen, C.sub.1 to C.sub.4 alkyl, amino or halo;
- R.sup.2 and R.sup.4 are each independently selected from hydrogen, C.sub.1 to C.sub.4 alkyl, fluoro, chloro and bromo or, together with the carbon atom to which they are attached, form a C.sub.3 to C.sub.6 cycloalkyl group;
- R.sup.6 and R.sup.8 are each independently selected from hydrogen, C.sub.1 to C.sub.4 alkyl, fluoro, chloro and bromo;
- or, when R.sup.2 and R.sup.4 do not form part of a cycloalkyl group, R.sup.2 and R.sup.6, together with the carbon atoms to which they are attached, may form a C.sub.5 to C.sub.7 cycloalkyl group;
- R.sup.7 is hydrogen, C.sub.1 to C.sub.4 alkyl optionally substituted with one or more halo, or C.sub.1 to C.sub.4 alkoxy; and
- n is 0, 1 or 2.
- 2. A compound according to claim 1 wherein R.sup.1 is 2,6-dichloro-4-trifluoromethylphenyl, 2,6-dichloro-4-pentafluorothiophenyl, 2,4,6-trichlorophenyl or 3-chloro-5-trifluoromethylpyridin-2-yl; R.sup.3 is methyl, ethyl, prop-2-yl, 1-hydroxyethyl, 2-hydroxyprop-2-yl, difluoromethyl, dichloromethyl, trifluoromethyl, cyano, formyl, acetyl or phenyl; R.sup.5 is hydrogen, methyl, amino or chloro; R.sup.2 and R.sup.4 are each independently selected from hydrogen, methyl, fluoro, chloro and bromo or, together with the carbon atom to which they are attached, form a cyclopropyl, cyclobutyl or cyclopentyl group; R.sup.6 and R.sup.8 are each independently selected from hydrogen, methyl, chloro and bromo; or, when R.sup.2 and R.sup.4 do not form part of a cycloalkyl group, R.sup.2 and R.sup.6, together with the carbon atoms to which they are attached, may form a cyclopentane or cyclohexane group; and R.sup.7 is hydrogen, methyl, ethyl, trifluoromethyl, chlorodifluoromethyl, pentafluoroethyl, heptafluoropropyl or methoxy.
- 3. A compound according to claim 2 wherein R.sup.1 is 2,6-dichloro-4-trifluoromethylphenyl, 2,6-dichloro-4-pentafluorothiophenyl or 3-chloro-5-trifluoromethylpyridin-2-yl; R.sup.3 is cyano; R.sup.5 is hydrogen or amino; R.sup.2 and R.sup.4 are the same and are hydrogen, chloro or bromo; R.sup.6 and R.sup.8 are hydrogen; and R.sup.7 is hydrogen, trifluoromethyl or chlorodifluoromethyl.
- 4. A compound according to claim 3 wherein the compound of formula (I) is selected from
- 3-cyano-4-(2,2-dibromocyclopropyl)-1-(2,6-dichloro-4-trifluoromethylphenyl)pyrazole;
- (-)-3-cyano-4-(2,2-dibromocyclopropyl)-1-(2,6-dichloro-4-trifluoromethylphenyl)pyrazole;
- 3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(1-trifluoromethylcyclopropyl)pyrazole;
- 3-cyano4-(2,2-dibromocyclopropyl)-1-(2,6-dichloro-4-pentafluorothiophenyl)pyrazole;
- 3-cyano-4-(2,2-dichlorocyclopropyl)-1-(2,6-dichloro-4-trifluoromethylphenyl)pyrazole;
- 4-(1-chlorodifluoromethylcyclopropyl)-3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)pyrazole;
- 1-[(3-chloro-5-trifluoromethyl)pyridin-2-yl]-3-cyano-4-(2,2-dibromocyclopropyl)pyrazole;
- 5-amino-3-cyano-4-(2,2-dibromocyclopropyl)-1-(2,6-dichloro-4-trifluoromethylphenyl)pyrazole;
- 5-amino-3-cyano-4-(2,2-dibromocyclopropyl)-1-(2,6-dichloro-4-pentafluorothiophenyl)pyrazole;
- 5-amino-3-cyano-4-(2,2-dichlorocyclopropyl)-1-(2,6-dichloro-4-pentafluorothiophenyl)pyrazole; and
- 5-amino-3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(1-trifluoromethylcyclopropyl)pyrazole.
- 5. A veterinary or agricultural formulation comprising a compound of claim 1, or a veterinarily or agriculturally acceptable salt thereof, or a veterinarily or agriculturally acceptable solvate of either entity, together with a veterinarily or agriculturally acceptable diluent or carrier.
- 6. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, together with a pharmaceutically acceptable diluent or carrier.
- 7. A method of treating a parasitic infestation in an animal (including a human being) which comprises treating said animal with an effective amount of a compound of claim 1, or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity, or a pharmaceutical composition or veterinary formulation containing any of the foregoing.
- 8. A method of treating a parasitic infestation at a locus which comprises treating said locus with an effective amount of a compound of claim 1, or a veterinarily or agriculturally acceptable salt thereof, or a veterinarily or agriculturally acceptable solvate of either entity, or a veterinary or agricultural formulation containing any of the foregoing.
- 9. A method as defined in claim 8 wherein the locus is the skin or fur of an animal, or a plant surface, or the soil around the plant to be treated.
- 10. A process for the preparation of a compound of formula (I): ##STR10## or a pharmaceutically, veterinarily or agriculturally acceptable salt thereof, or a pharmaceutically, veterinarily or agriculturally acceptable solvate of either entity,
- wherein
- R.sup.1 is 2,4,6-trisubstituted phenyl wherein the 2- and 6-substituents are each independently selected from halo and the 4-substituent is selected from C.sub.1 to C.sub.4 alkyl optionally substituted with one or more halo, C.sub.1 to C.sub.4 alkoxy optionally substituted with one or more halo, S(O).sub.n C.sub.1 to C.sub.4 alkyl optionally substituted with one or more halo, halo and pentafluorothio; or 3,5-disubstituted pyridin-2-yl wherein the 3-substituent is halo and the 5-substituent is selected from C.sub.1 to C.sub.4 alkyl optionally substituted with one or more halo, C.sub.1 to C.sub.4 alkoxy optionally substituted with one or more halo, S(O).sub.n C.sub.1 to C.sub.4 alkyl optionally substituted with one or more halo, halo and pentafluorothio;
- R.sup.3 is C.sub.1 to C.sub.4 alkyl optionally substituted with hydroxy or with one or more halo; cyano, C.sub.1 to C.sub.5 alkanoyl or phenyl;
- R.sup.5 is hydrogen, C.sub.1 to C.sub.4 alkyl, amino or halo;
- R.sup.2 and R.sup.4 are each independently selected from hydrogen, C.sub.1 to C.sub.4 alkyl, fluoro, chloro and bromo or, together with the carbon atom to which they are attached, form a C.sub.3 to C.sub.6 cycloalkyl group;
- R.sup.6 and R.sup.8 are each independently selected from hydrogen, C.sub.1 to C.sub.4 alkyl, fluoro, chloro and bromo;
- or, when R.sup.2 and R.sup.4 do not form part of a cycloalkyl group, R.sup.2 and R.sup.6, together with the carbon atoms to which they are attached, may form a C.sub.5 to C.sub.7 cycloalkyl group;
- R.sup.7 is hydrogen, C.sub.1 to C.sub.4 alkyl optionally substituted with one or more halo, or C.sub.1 to C.sub.4 alkoxy; and
- n is 0, 1 or 2;
- which comprises treatment of a compound of formula (II): ##STR11## wherein R.sup.1, R.sup.3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are as previously defined for formula (I),
- (a) when R.sup.2 and R.sup.4 are either both chloro or both bromo,
- (i) with chloroform or bromoform in the presence of a base, or
- (ii) with an aryltrichloromethyl or aryltribromomethyl mercury derivative under thermolysis conditions; or
- (b) when R.sup.2 and R.sup.4 are each independently hydrogen or C.sub.1 to C.sub.4 alkyl,
- (i) with the corresponding diazoalkane in the presence of a transition metal catalyst, or
- (ii) with, in a first step, the corresponding diazoalkane in the absence of a transition metal catalyst followed by, in a second step, thermolysis of the intermediate pyrazoline; optionally followed by formation of a pharmaceutically, veterinarily or agriculturally acceptable salt of the required product or a pharmaceutically, veterinarily or agriculturally acceptable solvate of either entity.
- 11. A process according to claim 10 wherein in
- (a) (i) the base is a concentrated aqueous solution of an alkali metal hydroxide and the reaction is conducted under phase transfer catalysis conditions using a quaternary ammonium salt as catalyst in a suitable solvent at from about room temperature to about the reflux temperature of the reaction medium; in
- (a) (ii) the reagent is either phenyltrichloromethylmercury or phenyltribromomethylmercury and the reaction is conducted in a suitable solvent at from about 60.degree. C. to about 75.degree. C.; in
- (b) (i), when R.sup.2 and R.sup.4 are both hydrogen, the diazoalkane is diazomethane, the catalyst is palladium(II) acetate and the reaction is conducted in a suitable solvent at about room temperature; and in
- (b) (ii), when R.sup.2 and R.sup.4 are both hydrogen, in the first step the diazoalkane is diazomethane and the reaction is conducted in a suitable solvent at about room temperature and, in the second step, the thermolysis of the isolated pyrazoline is conducted in a suitable solvent at from about 135.degree. C. to about 145.degree. C.
- 12. A process according to claim 11 wherein in
- (a) (i) the base is a concentrated aqueous solution of sodium hydroxide, the catalyst is benzyltriethylammonium chloride and the solvent is dichloromethane optionally in the presence of a small amount of ethanol; in
- (a) (ii) the solvent in toluene, xylene or a mixture thereof; in
- (b) (i) the solvent is ether; and in
- (b) (ii) the solvent in the first step is ether and in the second step is xylene.
- 13. A process for the preparation of a compound of formula (I) as defined in claim 10 which comprises thermolysis of an alkali metal salt derivative of a compound of formula (VII): ##STR12## wherein Ar is phenyl or naphthyl either of which is optionally substituted with C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.4 alkoxy or halo; R.sup.5 is hydrogen, C.sub.1 to C.sub.4 alkyl or halo; R.sup.7 is hydrogen or C.sub.1 to C.sub.4 alkyl optionally substituted with one or more halo; and R.sup.1 and R.sup.3 are as previously defined in claim 10, in the presence of a compound of formula (VIII): ##STR13## wherein R.sup.2, R.sup.4, R.sup.6 and R.sup.8 are as previously defined in claim 10, in the presence of a transition metal catalyst optionally in a suitable solvent optionally under pressure;
- optionally followed by formation of a pharmaceutically, veterinarily or agriculturally acceptable salt of the required product or a pharmaceutically, veterinarily or agriculturally acceptable solvate of either entity.
- 14. A process according to claim 13 wherein the transition metal catalyst is rhodium(II) acetate, the solvent is dichloromethane and the reaction is conducted at a pressure of from about 101 kPa (14.7 psi) to about 2757 kPa (400 psi) and a temperature of from about room temperature to about 80.degree. C.
- 15. A process according to claim 13 wherein Ar is 4-methylphenyl.
- 16. A process according to claim 10 wherein R.sup.1 is 2,6-dichloro-4-trifluoromethylphenyl, 2,6-dichloro-4-pentafluorothiophenyl, 2,4,6-trichlorophenyl or 3-chloro-5-trifluoromethylpyridin-2-yl; R.sup.3 is methyl, ethyl, prop-2-yl, 1-hydroxyethyl, 2-hydroxyprop-2-yl, difluoromethyl, dichloromethyl, trifluoromethyl, cyano, formyl, acetyl or phenyl; R.sup.5 is hydrogen, methyl, amino or chloro; R.sup.2 and R.sup.4 are each independently selected from hydrogen, methyl, fluoro, chloro and bromo or, together with the carbon atom to which they are attached, form a cyclopropyl, cyclobutyl or cyclopentyl group; R.sup.6 and R.sup.8 are each independently selected from hydrogen, methyl, chloro and bromo; or, when R.sup.2 and R.sup.4 do not form part of a cycloalkyl group, R.sup.2 and R.sup.6, together with the carbon atoms to which they are attached, may form a cyclopentane or cyclohexane group; and R.sup.7 is hydrogen, methyl, ethyl, trifluoromethyl, chlorodifluoromethyl, pentafluoroethyl, heptafluoropropyl or methoxy.
- 17. A process according to claim 16 wherein wherein R.sup.1 is 2,6-dichloro-4-trifluoromethylphenyl, 2,6-dichloro-4-pentafluorothiophenyl or 3-chloro-5-trifluoromethylpyridin-2-yl; R.sup.3 is cyano; R.sup.5 is hydrogen or amino; R.sup.2 and R.sup.4 are the same and are hydrogen, chloro or bromo; R.sup.6 and R.sup.8 are hydrogen; and R.sup.7 is hydrogen, trifluoromethyl or chlorodifluoromethyl.
- 18. A process according to claim 17 wherein the compound of formula (I) produced is selected from
- 3-cyano-4-(2,2-dibromocyclopropyl)-1-(2,6-dichloro-4-trifluoromethylphenyl)pyrazole;
- (-)-3-cyano-4-(2,2-dibromocyclopropyl)-1-(2,6-dichloro-4-trifluoromethylphenyl)pyrazole;
- 3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(1-trifluoromethylcyclopropyl)pyrazole;
- 3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(1-trifluoromethylcyclopropyl)pyrazole;
- 3-cyano-4-(2,2-dibromocyclopropyl)-1-(2,6-dichloro-4-pentafluorothiophenyl)pyrazole;
- 3-cyano-4-(2,2-dichlorocyclopropyl)-1-(2,6-dichloro-4-trifluoromethylphenyl)pyrazole;
- 4-(1-chlorodifluoromethylcyclopropyl)-3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)pyrazole;
- 1-[(3-chloro-5-trifluoromethyl)pyridin-2-yl]-3-cyano-4-(2,2-dibromocyclopropyl)pyrazole;
- 5-amino-3-cyano-4-(2,2-dibromocyclopropyl)-1-(2,6-dichloro-4-trifluoromethylphenyl)pyrazole;
- 5-amino-3-cyano-4-(2,2-dibromocyclopropyl)-1-(2,6-dichloro-4-pentafluorothiophenyl)pyrazole;
- 5-amino-3-cyano-4-(2,2-dichlorocyclopropyl)-1-(2,6-dichloro-4-pentafluorothiophenyl)pyrazole; and
- 5-amino-3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(1-trifluoromethylcyclopropyl)pyrazole.
- 19. A process according to claim 14 wherein Ar is 4-methylphenyl.
Priority Claims (3)
Number |
Date |
Country |
Kind |
96252903 |
Dec 1996 |
GBX |
|
97022354 |
Feb 1997 |
GBX |
|
97120455 |
Jun 1997 |
GBX |
|
Parent Case Info
The present application is the national stage, under 35 USC section 371, of PCT/EP97/06697, internationally filed on Nov. 25, 1997, and claiming priority of Great Britain Specifications 9625290.3, 9702235.4, and 9712045.5, filed respectively on Dec. 5, 1996, Feb. 4, 1997, and Jun. 10, 1997.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/EP97/06697 |
11/25/1997 |
|
|
6/3/1999 |
6/3/1999 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO98/24767 |
6/11/1998 |
|
|
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5232940 |
Hatton et al. |
Aug 1993 |
|
5547974 |
Hatton et al. |
Aug 1996 |
|
Foreign Referenced Citations (21)
Number |
Date |
Country |
0050335 |
Apr 1982 |
EPX |
0234119 |
Sep 1987 |
EPX |
0249409 |
Dec 1987 |
EPX |
0273862 |
Jul 1988 |
EPX |
0280991 |
Sep 1988 |
EPX |
0295117 |
Dec 1988 |
EPX |
0295118 |
Dec 1988 |
EPX |
0579280 |
Jan 1994 |
EPX |
0780378 |
Jun 1997 |
EPX |
1586258 |
Mar 1981 |
GBX |
2086302 |
Apr 1982 |
GBX |
WO9306089 |
Apr 1993 |
WOX |
9416732 |
Aug 1994 |
WOX |
9524219 |
Sep 1995 |
WOX |
9707102 |
Feb 1997 |
WOX |
9711602 |
Apr 1997 |
WOX |
9712521 |
Apr 1997 |
WOX |
9736484 |
Oct 1997 |
WOX |
9736483 |
Oct 1997 |
WOX |
9736485 |
Oct 1997 |
WOX |
9736486 |
Oct 1997 |
WOX |
Non-Patent Literature Citations (1)
Entry |
Elkaschef et al., Chemical Abstracts, vol. 81, No. 1520695, 1974. |